Pure red blood cell aplasia: patient management pitfalls in major ABO-incompatible haematopoietic cell transplantation

Garrett S Booth¹, Bipin N Savani^{2

3}, Amelia A Langston⁴

Affiliations

¹ The Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
² The Department of Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Tennessee Valley Veterans Affairs Hospital, Nashville, TN, USA.
⁴ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Comment

Garrett S Booth et al. Br J Haematol. 2021 May.

. 2021 May;193(4):701-702.

doi: 10.1111/bjh.17465. Epub 2021 Apr 12.

Garrett S Booth¹, Bipin N Savani^{2

3}, Amelia A Langston⁴

¹ The Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
² The Department of Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Tennessee Valley Veterans Affairs Hospital, Nashville, TN, USA.
⁴ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

No abstract available

Comment on

Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study.
Longval T, Galimard JE, Leprêtre AC, Suarez F, Amiranoff D, Cazaux M, Kaphan E, Michonneau D, Dhedin N, Coman T, Nguyen Quoc S, Peffault de Latour R, Resche-Rigon M, Sicre de Fontbrune F. Longval T, et al. Br J Haematol. 2021 May;193(4):814-826. doi: 10.1111/bjh.17463. Epub 2021 Apr 12. Br J Haematol. 2021. PMID: 33844842 Clinical Trial.

1. Longval T, Galimard JE, Leprêtre AC, Suarez F, Amiranoff D, et al. Treatment for pure red cell aplasia after major ABO incompatible allogeneic stem cell transplantation: a multicentric Study. Br J Haematol. 2021;193:814-826.
1. Wada S, Asano-Mori Y, Yamamoto H, Yuasa M, Kageyama K, Kaji D, et al. No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation. Bone Marrow Transplant. 2019;54(5):765-8.
1. Griffith LM, McCoy JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128(5):668-75.
1. Lally K, Kruse RL, Smetana H, Davis R, Roots A, et al. Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing. Transfusion. 2020;60(3):628-36.
1. Nayak S, Makroo RN, Prakash B, Chandra T, Agrawal S, et al. Comparative evaluation of five different methods of anti-ABO antibody titration: an aid for ABO-incompatible organ transplants. Ther Apher Dial. 2019;23(1):86-91.